We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NanoViricides - Nanobiotechnology
NNVC 7.520+2.6%May 29 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: donpat who wrote (1186)2/7/2019 5:34:27 PM
From: donpat of 1214
The trial targeted only breast cancer patients, but Lisanti is excited about extending the investigation to include other cancer types and a much larger number of patients.

He is now looking ahead to doxycycline one day being administered to cancer patients as an add on to the current standard of care, chemotherapy – should a Phase III trial prove successful.

Already, Lisanti and Sotgia have attracted a lot of interest from physicians keen to test the discovery on their own patients, and a number of people have reported benefitting from the findings.

“Obviously there is a lot more work to be done,” Lisanti says, “but in controlled settings, doxycycline seems to be working as predicted, which is hugely promising.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext